Klebsiella Spp: Infections, Resistance, and Prevention

Klebsiella species are among the most consequential bacterial pathogens in hospitals worldwide, responsible for a large share of healthcare-associated pneumonia, bloodstream infections, and urinary tract infections. The genus is dominated by Klebsiella pneumoniae, a gut-dwelling organism that becomes dangerous when it reaches the lungs, bloodstream, or urinary tract, particularly in people whose immune defenses are already compromised. What makes Klebsiella especially worrying in the 2020s is not just the infections themselves but the accelerating convergence of drug resistance and heightened virulence in a single organism, a combination that shrinks treatment options while the bacterium becomes more capable of causing severe disease.

The Gut as Ground Zero

Most Klebsiella infections do not begin with a cough or a contaminated surface. They begin in the patient’s own intestine. The primary risk factor for a K. pneumoniae infection is prior colonization of the gastrointestinal tract, and in many cases the infecting strain turns out to be the same one already living in the gut.¹ This is why hospital patients are so vulnerable: antibiotics wipe out much of the normal gut flora, giving Klebsiella room to bloom. Once it dominates the intestinal environment, any breach, whether from a catheter, a surgical wound, or simply a weakened immune system, can let the organism reach sterile body sites.

For carbapenem-resistant strains in particular, the path from gut colonization to active infection is well documented. Patients who carry these resistant strains in their intestines face an elevated risk of secondary infection during hospitalization. Common triggers include invasive procedures, intensive care unit stays, prolonged antibiotic courses, advanced age, and serious underlying conditions such as kidney failure or coma.² The hands of healthcare workers also serve as a transmission route, transferring Klebsiella from one patient’s environment to another and seeding outbreaks across hospital wards.³

How Klebsiella Evades the Immune System

Klebsiella’s success as a pathogen rests on a toolkit of virulence factors, and the thick sugar capsule surrounding the cell is arguably the most important one. This capsular polysaccharide acts as a physical shield. It does not directly provoke a harmful immune response; instead, it coats the bacterium’s outer surface and blocks the receptor proteins that immune cells would normally latch onto, preventing the white blood cells from recognizing and engulfing it.⁴ Real-time imaging in animal models shows the effect vividly: capsule-free Klebsiella mutants injected into the bloodstream are rapidly captured and killed by specialized liver immune cells called Kupffer cells, while encapsulated strains sail past them. The degree of protection depends on the capsule serotype, with certain types conferring much greater evasion than others.⁵

Iron scavenging is the second major weapon. Inside the human body, free iron is kept at vanishingly low levels as an antimicrobial defense. Klebsiella fights back by producing small molecules called siderophores that grab iron from host proteins and shuttle it back to the bacterium. K. pneumoniae can produce up to four different siderophores, each suited to a different body site. Aerobactin, found in the vast majority of hypervirulent strains, accounts for most of the total iron-gathering activity and is especially important for colonizing the gut and establishing lung infections. Salmochelin, a modified version of the more common enterobactin, helps the bacterium dodge a host defense protein that would otherwise neutralize ordinary siderophores, making strains that produce it more virulent in tissue infections.⁶⁷

Beyond the capsule and siderophores, some strains also suppress the immune system’s more creative defenses. Neutrophils, the first-responder white blood cells, can fling out webs of DNA and antimicrobial proteins called neutrophil extracellular traps (NETs) to snare and kill bacteria. Carbapenem-resistant K. pneumoniae of the globally dominant ST258 lineage can shut down this NET release entirely and also block the deployment of the neutrophil’s most potent bactericidal granules.⁸ People with type 2 diabetes face a double disadvantage: while their neutrophils actually form more NETs than normal, these traps are less effective at damaging the bacterial surface, leaving hypervirulent Klebsiella relatively unscathed.⁹

Classical Versus Hypervirulent Strains

Not all K. pneumoniae strains are created equal. The medical world increasingly divides them into two broad pathotypes. Classical strains (cKp) are the familiar hospital bugs, usually causing infections in immunocompromised patients and often carrying extensive drug resistance. Hypervirulent strains (hvKp) are a different animal: they can cause life-threatening infections even in young, otherwise healthy people, and they tend to produce thicker capsules, more siderophores, and stickier biofilms.¹⁰

The clinical hallmark of hypervirulent Klebsiella is Invasive Liver Abscess Syndrome. A patient, often with no underlying illness, develops a pyogenic liver abscess that can seed secondary infections in distant organs, including the eyes (endogenous endophthalmitis), the lungs, and the prostate. This syndrome has historically been most common in East and Southeast Asia, but travel to Asia and Asian ethnicity are independent risk factors in Western countries, and non-Asian patients are affected too.¹¹ Cases have been documented across Europe in immunocompetent individuals with no recent Asian travel.¹²

Distinguishing hypervirulent from classical strains in the lab matters because it affects treatment urgency and surveillance decisions. Researchers have found that simply counting the number of key virulence genes a strain carries, specifically a panel of five markers, is the strongest single predictor. In one study, strains carrying all five markers were classified as hypervirulent with about 94% accuracy.¹³ At the molecular level, hypervirulent isolates also show distinct patterns of DNA methylation, with higher overall methylation in their virulence-related genes and capsule-synthesis regions compared to classical strains.¹⁴

The Resistance Problem

Klebsiella is a natural collector of antibiotic resistance genes. It picks them up on mobile genetic elements, particularly plasmids, and shares them with neighboring bacteria with alarming ease. The resistance story has unfolded in waves, each one eliminating another class of drugs.

The first major wave involved extended-spectrum beta-lactamases (ESBLs), enzymes that break down penicillins and many cephalosporins. ESBL-producing Klebsiella became widespread in hospitals starting in the 1990s, rendering a long list of standard antibiotics useless. Common ESBL gene families found in clinical isolates include the TEM, CTX-M, and SHV types, sometimes carried together on the same plasmid.¹⁵ ESBLs spare a few older drugs and, critically, they spare carbapenems, which became the go-to treatment for serious ESBL infections.¹⁶

The second wave arrived when Klebsiella acquired carbapenemases, enzymes that destroy carbapenems themselves. The KPC (Klebsiella pneumoniae carbapenemase) family spread globally and became the dominant mechanism in many regions. The NDM (New Delhi metallo-beta-lactamase) family followed, spreading particularly rapidly across South and Southeast Asia. Each of these enzymes sits on a plasmid that can jump between bacterial species, meaning resistance does not stay confined to Klebsiella. In some clinical isolates, both KPC and NDM are now found together on separate plasmids within the same cell, creating strains that resist essentially all beta-lactam antibiotics, including the newer beta-lactamase inhibitor combinations.¹⁷ Genomic tracking has shown that some KPC/NDM co-producing strains arise when a patient already colonized with a KPC-carrying strain acquires an NDM-carrying plasmid during treatment, sometimes in response to newer antibiotics like ceftazidime-avibactam that are effective against KPC but not NDM.¹⁸

Colistin, a decades-old antibiotic pulled from the shelf as a last resort against pan-resistant infections, is also under threat. Klebsiella can develop colistin resistance through mutations that inactivate a regulatory gene called mgrB, either by point mutations or by insertion sequences that disrupt it.¹⁹ When colistin resistance overlaps with carbapenem resistance, the remaining treatment options become extremely narrow.

When Resistance Meets Hypervirulence

For years, drug resistance and hypervirulence traveled in largely separate Klebsiella lineages. Classical hospital strains accumulated resistance but were relatively weak pathogens; hypervirulent community strains were devastating but usually susceptible to antibiotics. That separation is breaking down. Researchers have documented the emergence of “superplasmids,” single self-transmissible plasmids that carry both hypervirulence genes and multidrug resistance genes on the same genetic element. One such superplasmid was found to include a complete conjugation apparatus, meaning it can transfer itself to new bacterial hosts, and it showed a retention rate above 95% once acquired, making it extremely stable.²⁰

Clinical isolates that combine KPC-2, NDM-5, and virulence plasmids in a single cell have now been identified. These strains resist carbapenems and newer beta-lactamase inhibitor combinations while also showing high pathogenicity in cell-culture and animal infection models.²¹ The prospect of a Klebsiella strain that is simultaneously hard to treat and capable of infecting healthy people is one of the more alarming developments in infectious disease today.

Current Treatment of Drug-Resistant Infections

When carbapenem-resistant K. pneumoniae causes a bloodstream infection, the antibiotic ceftazidime-avibactam has emerged as the most effective available option for strains carrying KPC-type enzymes. In comparative studies, patients treated with ceftazidime-avibactam had higher rates of clinical success and survival than those receiving other regimens.²² A meta-analysis confirmed lower 28-day and 30-day mortality with ceftazidime-avibactam compared to other antimicrobials for carbapenem-resistant Klebsiella infections broadly.²³

The catch is that ceftazidime-avibactam does not work against NDM-producing strains, because avibactam cannot inhibit metallo-beta-lactamases. This creates a troubling feedback loop: using ceftazidime-avibactam against KPC-carrying strains in a patient who is also colonized by NDM-carrying bacteria can select for the acquisition of NDM plasmids, generating dual-carbapenemase strains that resist both old and new drugs.¹⁸ Newer agents targeting metallo-beta-lactamases are in clinical development, but for now, clinicians facing KPC/NDM co-producers are left with very few options, sometimes only colistin-based combinations with all their toxicity.

Beyond K. pneumoniae

Although K. pneumoniae dominates the clinical conversation, it is not the only clinically relevant Klebsiella species. Klebsiella oxytoca causes a distinct disease: antibiotic-associated hemorrhagic colitis. Patients on antibiotics, particularly penicillin-type drugs, can develop bloody diarrhea driven by cytotoxins that K. oxytoca produces when normal gut flora is suppressed. The toxins, called tilivalline and tilimycine, are encoded by specific gene clusters, and the disease is limited to toxin-producing strains.²⁴ The syndrome was definitively linked to K. oxytoca in a study that reproduced hemorrhagic colitis in an animal model, confirming it was not merely a bystander finding.²⁵ Diagnosing this correctly matters because it means stopping the offending antibiotic rather than adding another one.

Telling Klebsiella species apart in the clinical lab has historically been tricky, but newer mass spectrometry methods have improved matters. Using species-specific marker masses, MALDI-TOF instruments can now distinguish eight Klebsiella species, a level of resolution that helps clinicians match the right treatment to the right bug.²⁶ Rapid phenotypic tests are also gaining ground for resistance detection: automated microscopy systems that track bacterial growth in the presence of antibiotics can identify carbapenem resistance and KPC production in K. pneumoniae within hours rather than the days conventional culture requires.²⁷

Environmental Reservoirs and the One Health Angle

Klebsiella is not exclusively a hospital problem. Environmental surveys find K. pneumoniae as the most common Klebsiella species in both soil and surface water, and it frequently carries multidrug-resistance profiles in these settings. The detection of high-risk sequence types like ST11, ST15, and ST147 in environmental samples suggests that human and animal waste is seeding resistant Klebsiella back into the broader ecosystem.²⁸ This creates a cycle: resistant strains emerge in hospitals, enter wastewater, persist in the environment, and potentially re-colonize people through contaminated food or water. Agricultural antibiotic use adds another selective pressure. Breaking this cycle requires coordination between human healthcare, veterinary medicine, and environmental management, the approach known as One Health.

Infection Control in Hospitals

Given the gut colonization pathway, preventing Klebsiella infections means finding carriers before they develop active disease and interrupting transmission between patients. A combination of active rectal surveillance to identify colonized patients, strict contact precautions, enhanced hand hygiene, and cohorting of carriers has been shown to work. One hospital intervention that increased active surveillance from about 20% to 89% of at-risk patients achieved a 16-fold reduction in carbapenem-resistant K. pneumoniae incidence, sustained over two and a half years. The cross-infection rate, from roughly 6% to under 3%, dropped alongside.²⁹

Urinary catheters deserve specific mention because they are one of the most common entry points for Klebsiella urinary tract infections. Klebsiella readily forms biofilms on catheter surfaces using specialized adhesion structures called fimbriae, which anchor the bacteria to the inert material and make the resulting colonies far harder to dislodge or kill with antibiotics.³⁰ Removing unnecessary catheters as early as possible remains one of the simplest and most effective preventive measures. Bundled catheter-care protocols, including aseptic insertion technique, closed drainage systems, and daily reassessment of catheter necessity, are standard practice in hospitals that take Klebsiella seriously.

Phage Therapy and Vaccines on the Horizon

With antibiotic options dwindling, bacteriophages, viruses that specifically target bacteria, are attracting serious research attention for Klebsiella infections. A novel phage species active against multidrug-resistant K. pneumoniae was recently characterized and found to carry no resistance or virulence genes of its own, an important safety criterion. In a wax moth larval model, phage treatment improved survival compared to untreated controls.³¹ Early-stage strategies include phage cocktails (mixtures that reduce the chance of resistance evolving to any single phage), combinations of phages with conventional antibiotics, and treatments based on phage-derived enzymes that degrade bacterial cell walls.³² Phage therapy remains largely experimental and available mainly through compassionate-use programs, but the pipeline is active and growing.

Vaccine development is also underway, targeting the capsular polysaccharides that make Klebsiella so hard for the immune system to handle. Because different Klebsiella strains wear different capsule types, effective vaccines probably need to be multivalent. One experimental approach created a four-component vaccine covering four major capsular serotypes, including those associated with both hypervirulent and drug-resistant lineages, and demonstrated protection in mouse models of bloodstream infection, even in immunocompromised animals.³³ No Klebsiella vaccine has reached late-stage clinical trials in humans yet, but the technology for producing capsular bioconjugate vaccines has matured enough that multiple candidates are moving through the development pipeline.³⁴ Given that hospital infection control can only slow the problem and antibiotics are losing ground, a working vaccine would change the equation fundamentally for the patients most at risk, those facing surgery, cancer treatment, or long intensive care stays.